Although available studies do not adequately demonstrate the direct role of PI3K signaling in commencing metabolic reprogramming of PDAC cells, future studies directed toward elucidating the interplay between this tumorigenic metabolic pathway with PDAC metabolism will potentially identify new test models and therapeutic options for pancreatic cancer. This evidence concerns the gene PIK3CD and pancreatic neoplasm.